Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. - Wikidata - awgldk - TriplyDB

Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug.

Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug.

http://www.wikidata.org/entity/Q33747286

about

Obstetrical antiphospholipid syndrome: from the pathogenesis to the clinical and therapeutic implications Antiphospholipid antibodies and the placenta: a systematic review of their in vitro effects and modulation by treatment Examining the prevalence of non-criteria anti-phospholipid antibodies in patients with anti-phospholipid syndrome: a systematic review Antigen and substrate withdrawal in the management of autoimmune thrombotic disorders.Review on Effectiveness of Primary Prophylaxis in aPLs with and without Risk Factors for Thrombosis: Efficacy and Safety Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression.Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of β2-glycoprotein I.Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management.Atomic force microscopy: High resolution dynamic imaging of cellular and molecular structure in health and disease.Resistance to annexin A5 anticoagulant activity in women with histories for obstetric antiphospholipid syndrome Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management-An Insight into Future Approaches.Antiphospholipid Syndrome during pregnancy: the state of the art Insights into the pathophysiology of the antiphospholipid syndrome provided by atomic force microscopy.Pathophysiological mechanisms in antiphospholipid syndrome Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus Improving outcomes in patients with lupus and end-stage renal disease.Recent advances in understanding antiphospholipid syndrome.Hydroxychloroquine: from malaria to autoimmunity.Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report.New insights into mechanisms of therapeutic effects of antimalarial agents in SLE.Emerging Therapies in Antiphospholipid Syndrome.Immunotherapeutic strategies in antiphospholipid syndrome.The antiphospholipid syndrome: from pathophysiology to treatment.Pregnancy Outcome in Women with Obstetric and Thrombotic Antiphospholipid Syndrome-A Retrospective Analysis and a Review of Additional Treatment in Pregnancy.Hydroxychloroquine restores trophoblast fusion affected by antiphospholipid antibodies.Hydroxychloroquine in systemic lupus erythematosus (SLE).Novel diagnostic and therapeutic frontiers in thrombotic anti-phospholipid syndrome.Pathogenesis and management of antiphospholipid syndrome.Emerging Treatment Models in Rheumatology: Antiphospholipid Syndrome and Pregnancy: Pathogenesis to Translation.Factor Xa Mediates Calcium Flux in Endothelial Cells and is Potentiated by Igg From Patients With Lupus and/or Antiphospholipid Syndrome.Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome.A new trick for an ancient drug: quinine dissociates antiphospholipid immune complexes.Recurrent thrombosis prevention with intravenous immunoglobulin and hydroxychloroquine during pregnancy in a patient with history of catastrophic antiphospholipid syndrome and pregnancy loss.Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).The effect of hydroxychloroquine on haemostasis, complement, inflammation and angiogenesis in patients with antiphospholipid antibodies.Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease.Diagnosis and management of the antiphospholipid syndrome.Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus.

P2860

Q26998188-6A41A63D-E718-447C-AD15-3071FBC5C00A Q26999710-F840361A-4C67-4B08-B7FF-DC0D97CBB1EC Q28081765-FBD414FA-6989-4245-AA74-37BEA6ACA511 Q33403225-35A27A02-476D-4E40-8CEF-A20830AEA893 Q33692770-CBAD9CFA-CF64-4F5F-9315-71CEBEF5F7C2 Q34003992-F2A28D01-E029-4CA5-A212-6FD1D88FB6AB Q34069117-21AB650B-C75A-4793-B5F8-7EA32D1A22B0 Q34161393-F8931533-A049-465B-90A3-3FE2684C57FD Q34476952-6413BB51-33FF-42EB-983F-975164C6E300 Q34633803-91EE230E-1FE5-4998-9B78-1C5596A74BDF Q35490209-A20BC46D-7E65-4EEF-B066-FBF1AB5BE796 Q35621012-14355925-3D7F-4BB1-B435-FC22C70623A7 Q35756040-7473E8B3-B03E-426A-A67F-02C294761901 Q35927360-8D6F5862-D8ED-4946-BAA6-7A1006161B00 Q36671159-FCAB4A25-5755-4C25-84FC-E93218A10AB5 Q37158591-03CDF42F-5DE7-469C-98A1-09A4F9816990 Q37522782-8BA0B40F-49F5-40E5-BB5C-C9F8DCC3CD1D Q37577693-2B2A1358-6FB1-425D-935A-3BF6533A69C6 Q37827403-290E58C5-D594-44D9-BFDD-ACC377DE0FC9 Q37954539-A76781C2-769C-47F6-8D85-1811F04D7482 Q38026787-207769E9-422E-4ADF-AC75-EF58F734EB2F Q38782057-27015920-7DA8-43FB-8496-DAC613E3B291 Q38826804-5E90D93C-5ADA-43CE-9E54-DB1FF897879B Q38873953-8C94A489-D988-40E5-8C03-8CAD5B1B2BB3 Q38891094-140F5597-A796-4B76-BDA7-0114D2B9BF6C Q39013184-A1FBA0CE-B26A-454E-A533-F6F8DF185B3C Q39031764-7275C870-F799-4AE7-B481-2CC2AB82EC4E Q39065301-0A734D46-2C8A-4D55-9E7D-40C9257DAF9D Q39198671-9C9ED014-FEA6-468B-ABFE-14DBB235D716 Q39264755-A39CD9A6-1613-4543-BA30-267A2BD19FF6 Q41546012-20CC58F0-80DA-4466-BF92-ACB8DE1D16B2 Q41915133-71CF3CB8-735B-4074-BC1E-F53BC095B52B Q41920381-5CC7C2EB-3689-4717-B004-FA7CB9D0C660 Q41922298-29586960-DACC-4321-AF0F-225FB3048AB8 Q41927831-675DA544-CB81-4885-80AC-C6B9B695EB59 Q45873335-DCE150A7-0632-407E-B9AF-8AC64585B1D0 Q47680027-ABD74DE1-2E9F-4F09-B3FB-98433DE43355 Q47982275-FA135CD7-AE56-474B-BAF7-C879D1D6B982 Q52316454-2010A7E1-A1A0-4C2B-A3E4-81B9C6C497A9

P2860

Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug.

http://www.wikidata.org/entity/Q33747286

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Hydroxychloroquine protects th ...... for an old antimalarial drug.

@ast

Hydroxychloroquine protects th ...... for an old antimalarial drug.

@en

type

label

Hydroxychloroquine protects th ...... for an old antimalarial drug.

@ast

Hydroxychloroquine protects th ...... for an old antimalarial drug.

@en

prefLabel

Hydroxychloroquine protects th ...... for an old antimalarial drug.

@ast

Hydroxychloroquine protects th ...... for an old antimalarial drug.

@en

P1433

Q33747286-4724A667-A114-4431-8516-C3FCA2FE1368

P1476

Q33747286-E5EE1C1F-8AE3-435A-874C-A3B85EEB1A8A

P2093

Q33747286-150012F7-2AAC-476F-8052-EA6F7D0DC59E

Q33747286-30E78F2A-21EF-43F3-B1D4-BCE99BA8FC99

Q33747286-4AF69FF2-A0DE-4F57-A92F-B88410A49540

Q33747286-90B4E4EF-9BF7-491D-AE17-7498E20CB126

Q33747286-A7DAD29A-8A2B-427F-90EA-4D2B9AA7146F

Q33747286-B5419732-88A5-4801-87EA-314E0E5DAC85

Q33747286-B9EE9A79-1A06-4D81-928B-2AB7DEFFBEAD

Q33747286-CA3BB6E8-BAF0-4240-847B-605731187AF7

P2860

Q33747286-03814193-77CC-41F5-8BD7-478A06228F9E

Q33747286-039BF06B-DF12-4AED-BADD-5B335C1C4A0E

Q33747286-041DDFDF-88DE-4704-A337-D03CD2808CD8

Q33747286-066FD365-A0C5-484A-8D82-A469F289B601

Q33747286-0BA415E4-4952-4991-A86C-912F01C99D65

Q33747286-12DC9904-6572-42A8-BB9B-960AA443D3FB

Q33747286-19B4ED6C-64D8-4117-BF0E-CDD7B2727FEE

Q33747286-3C33E3A4-0FFA-4E92-AA33-B99CD16906DC

Q33747286-3EE67CAA-BCFA-42B8-AE85-F075C559E53E

Q33747286-4AA7F7EC-44F4-4DC2-AB37-95315EC75ED7

P304

Q33747286-6DC77809-5437-4C77-8863-C1D5B6789BB5

P31

Q33747286-5DF09844-9D26-41D6-ADFB-A685CEE72A0C

P356

Q33747286-057FB7B4-16F5-42CB-95F6-413A915569DA

P407

Q33747286-BFBD5A7E-B172-4EEA-A68C-82E1B2E5C087

P433

Q33747286-2685AF8B-9119-4C99-8AC6-9CC878E2BD8B

P478

Q33747286-325F0099-D775-46A2-BC24-42A4394F0B83

P577

Q33747286-7914C84B-824B-40D1-A596-4F1CB8425A98

P5875

Q33747286-D3AC1CDA-8BCE-430C-AB94-64FDA103E8B4

P698

Q33747286-F0FD1761-F7AA-4124-ADB4-2594E72F4AB2

P921

Q33747286-6BA1591A-DA30-4368-9F55-3310D6492F71

Q33747286-A3B630C4-0E01-4F74-A7C5-F438A31563D4

Q33747286-A3EBBF9C-5E55-4EA0-BC52-730FB3A58A94

Q33747286-C41C1E71-09FE-4394-941C-4E607AC83C31

P932

Q33747286-905BD9EB-D51A-4CF9-8616-B670B7554F88

P356

BLOOD-2009-04-213520

P1433

P1476

Hydroxychloroquine protects th ...... for an old antimalarial drug.

@en

P2093

Anthony S Quinn

http://www.w3.org/2001/XMLSchema#string

Anthony W Ashton

http://www.w3.org/2001/XMLSchema#string

Douglas J Taatjes

http://www.w3.org/2001/XMLSchema#string

Harry A M Andree

http://www.w3.org/2001/XMLSchema#string

Jacob H Rand

http://www.w3.org/2001/XMLSchema#string

James J Hathcock

http://www.w3.org/2001/XMLSchema#string

Pojen P Chen

http://www.w3.org/2001/XMLSchema#string

Xiao-Xuan Wu

http://www.w3.org/2001/XMLSchema#string

P2860

A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome

Management of antiphospholipid antibody syndrome: a systematic review

Placental anticoagulant proteins: isolation and comparative characterization four members of the lipocortin family

Antiphospholipid antibody syndrome: rapid, sensitive, and specific flow cytometric assay for determination of anti-platelet phospholipid autoantibodies.

Hydroxychloroquine in lupus pregnancy.

Prevalence of antiphospholipid antibodies in patients with fetal loss

Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort.

Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome.

Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay.

Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus

P304

2292-2299

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2009-04-213520

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P577

2009-11-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40452590

http://www.w3.org/2001/XMLSchema#string

P698

19965621

http://www.w3.org/2001/XMLSchema#string

P921

hydroxychloroquine

anticoagulation

P932

2844013

http://www.w3.org/2001/XMLSchema#string